AstraZeneca: Stifel's best pick in sector

(CercleFinance.com) - Stifel has reiterated its "buy" rating on AstraZeneca shares, which is its top pick for Q4 2022 amongst six major European pharmaceutical companies, having increased its target price for the share from 12,300 pence to 13300 pence.


The broker believes that the stock of the Swedish/British laboratory, which already has the best performance, will remain well positioned ahead of the publication of the TROPION-Lung 01 clinical study.

Stifel also maintains its "buy" ratings on Sanofi and Novo Nordisk shares, although has downgraded its rating on Roche shares to "hold", with it also having hold ratings on its peers Novartis and GSK.



Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.